Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Teva Pharmaceutical
Biotech
Teva saddles up as bidder for bankrupt BioXcel’s CNS assets
BioXcel Therapeutics has filed for bankruptcy and lined up a deal for Teva Pharmaceutical to acquire its assets for $57.5 million upfront.
Nick Paul Taylor
Aug 28, 2026 9:17am
Bionyra emerges with $165M and three licensed I&I assets
Jun 22, 2026 7:00am
Blackstone closes record $6.3B life sciences fund
Mar 30, 2026 1:50pm
Teva lines up $500M in Royalty Pharma funding for vitiligo drug
Jan 12, 2026 7:10am
Schizophrenia-minded Syremis takes off with $165M series A
Dec 18, 2025 12:59pm
Fierce Pharma
Teva debuts innovation platform to parry key industry challenges
Nov 19, 2025 8:38am
